A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
NCT ID: NCT06384261
Last Updated: 2025-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2024-07-22
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
NCT04801797
Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
NCT03573024
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993523
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
NCT06773208
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
NCT03932318
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Potential participants will be considered ineligible for intensive chemotherapy and, therefore, eligible for the study, if they meet the trial eligibility criteria and provide informed consent. Participants will undergo a diagnostic bone marrow biopsy and aspirate collected for pathology review, cytogenetics, fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR) analysis and other studies for confirmation of a diagnosis of AML and to define whether participants have adverse, intermediate, or favorable AML risk features. Participants will then be randomized 2:1 to either the experimental arm or the active comparator arm and stratified based on AML risk features (adverse, intermediate, and favorable risk).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cusatuzumab in combination with venetoclax and azacitidine
Cusatuzumab 20 mg/kg administered intravenously on days 3 and 17 in combination with venetoclax administered orally up to 400 mg once daily and azacitidine 75 mg/m\^2 administered subcutaneously or intravenously once daily for 7 days of a 28 day cycle
Cusatuzumab
CD70 monoclonal antibody
Venetoclax
BCL-2 inhibitor
Azacitidine
Hypomethylating agent
Venetoclax in combination with azacitidine
Venetoclax administered orally up to 400 mg once daily and azacitidine 75 mg/m\^2 administered subcutaneously or intravenously once daily for 7 days of a 28 day cycle
Venetoclax
BCL-2 inhibitor
Azacitidine
Hypomethylating agent
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cusatuzumab
CD70 monoclonal antibody
Venetoclax
BCL-2 inhibitor
Azacitidine
Hypomethylating agent
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for the study and is willing to participate in the study
* Diagnosis of AML according to ICC 2022 (with the exclusion of MDS/AML with 10-19% blasts)
* Previously untreated AML except may have received emergency leukapheresis, hydroxyurea before study entry to control hyperleukocytosis
* Deemed unfit for intensive chemotherapy by meeting at least 1 of the following criteria:
1. Participant is ≥75 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 OR
2. Participant is ≥18 to 74 years of age and has any of the following comorbidities:
1. ECOG performance status of 2 or 3
2. Cardiac status including any one of the following: congestive heart failure requiring treatment or ejection fraction ≤50% or chronic stable angina
3. Known history of diffusion capacity of lung for carbon monoxide (DLCO) ≤65% of forced expiratory volume in the first second (FEV1) ≤65%
4. Creatinine clearance (CrCl) ≥15 mL/min to \<45 mL/min
5. Hepatic disorder with total bilirubin \>1.5 to 3x the upper limit of normal (ULN)
6. Any other comorbidity that the investigators determine to be incompatible with conventional intensive chemotherapy
* Adequate liver and renal function defined as:
1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<3xULN; for participants with leukemic infiltration of the liver (documented by biopsy or imaging), AST and ALT \<5xULN is permitted
2. Total bilirubin ≤1.5xULN, unless bilirubin rise is due to Gilbert's syndrome or of nonhepatic origin. Participants who are \<75 years of age may have a bilirubin up to 3xULN.
3. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease \[MDRD\] formula). Participants who are \<75 years of age may have an eGFR ≥15 mL/min/1.73 m2.
* Women of childbearing potential (WOCBP), defined as fertile women between menarche and post menopause unless permanently sterile, must have a negative highly sensitive serum β-human chorionic gonadotropin (β-hCG) or urine pregnancy test at screening
* Must be willing to use contraception as consistent with institutional guidelines regarding the use of contraceptive methods for participants participating in clinical studies
1. WOCBP must agree to adhere to the following birth control measures while receiving study treatment continuing to 3 months after the last dose of study drug:
1. Must be practicing a highly effective method of birth control (failure rate of \<1% per year when used consistently and correctly) as determined by institutional standards
2. Must agree to not donate eggs (ova, oocytes) for the purposes of assisted reproduction
3. Must not be breastfeeding and not planning to become pregnant
2. Male participants who are sexually active with WOCBP, and male partners of study participants who are WOCBP, and who are not surgically or otherwise sterile must agree to adhere to the following birth control measures while receiving study treatment and for 3 months after the last dose of study drug:
1. Must agree to use a barrier method of birth control (e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap \[diaphragm or cervical/vault caps\] with spermicidal foam, gel, film, cream, or suppository)
2. Must not donate sperm
3. Must no plan to father a child
* Participants with HIV infection are eligible for the trial if the following criteria are met:
1. CD4+ T-cell count ≥200 cells/μL
2. No prior history of AIDS-defining opportunistic infection within the past 12 months
3. Receiving treatment with antiretroviral therapy
4. Undetectable viral load within 6 months of screening
Exclusion Criteria
* Participant has received a hypomethylating agent (HMA) or venetoclax for MDS or myeloproliferative neoplasm
* Leukemic involvement in the central nervous system
* Participants with acute promyelocytic leukemia (APL)
* ECOG performance status of 4 for participants 18 to 74 years of age and ECOG performance status of 3 or 4 for participants ≥75 years of age
* Use of immune suppressive agents ≤4 weeks before the first administration of cusatuzumab. Participants may be included if free of systemic corticosteroids \>5 days before the first administration of cusatuzumab with the exception of corticosteroids at physiologic replacement doses.
* Received a live, attenuated vaccine within 4 weeks prior to initiation of study drug
* Active malignancies (i.e., progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. Exceptions to this exclusion criterion include the following:
1. Nonmelanoma skin cancer treated within the last 24 months that is considered completely cured
2. Adequately treated breast lobular carcinoma in situ and breast ductal carcinoma in situ
3. Adequately treated cervical carcinoma in situ and breast ductal carcinoma in situ
4. History of localized breast cancer and receiving anti-hormonal agents, or history of localized prostate cancer (N0M0) and receiving androgen depravation therapy
5. A malignancy that is considered cured with minimal risk of recurrence
* Any active systemic infection
* History of prior HSCT (allogeneic or autologous transplants)
* Active hepatitis B or C infection or other clinically active liver diseases ad defined below:
1. Seropositivity for hepatitis B is defined by a positive test for hepatitis B surface antigen (HBsAg)
2. Participants with resolved infection (i.e., participants who are HBsAg negative with antibodies to total hepatitis B core antigen \[anti-HBc\] with or without the presence of hepatitis B surface antibody \[anti-HBs\]) must be screened using PCR measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded.
* Participants with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR
3. Active hepatitis C infection as defined by being positive for a nucleic acid test for hepatitis C virus (HCV) RNA
* Congestive hear failure severity that is New York Heart Association Class III or IV
* Unstable angina
* Known allergies, hypersensitivity, or intolerance to cusatuzumab, venetoclax, or azacitidine or their excipients (e.g., mannitol, an excipient of azacitidine)
* Inability or difficulty swallowing capsules/tablets, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function
* Any condition for which, in the investigator's opinion, participation would not be in the best interest of the participant (e.g., compromise the well-being) or physical limitations that could prevent, limit, or confound the protocol-specified assessments
* Major surgery (e.g., requiring general anesthesia) ≤4 weeks prior to initiation of study treatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OncoVerity, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner MD Anderson
Gilbert, Arizona, United States
City of Hope
Duarte, California, United States
University of California Los Angeles
Los Angeles, California, United States
University of Colorado Health - Anschutz Cancer Pavilion - Anschutz Medical Campus
Aurora, Colorado, United States
Yale School of Medicine
New Haven, Connecticut, United States
AdventHealth Medical Group Blood & Marrow Transplant at Orlando
Orlando, Florida, United States
The University of Iowa Hospitals & Clinics
Iowa City, Iowa, United States
University of Kentucky Chandler Medical Center
Lexington, Kentucky, United States
Norton Healthcare, Inc.
Louisville, Kentucky, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Hofstra/Northwell Health
Lake Success, New York, United States
Cornell University
New York, New York, United States
University of Rochester Medical Center
Rochester, New York, United States
Wake Forest North Carolina
Winston-Salem, North Carolina, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Fred Hutch Seattle Cancer Care Alliance
Seattle, Washington, United States
Medical College of Wisonsin
Milwaukee, Wisconsin, United States
Tom Baker Cancer Center-Alberta Health Services - University of Calgary
Calgary, Alberta, Canada
Stollery Children's Hospital-Walter C Mackenzie Health Sciences Centre - University of Alberta
Edmonton, Alberta, Canada
Vancouver General Hospital, Gordon and Leslie Diamond Health Care Centre
Vancouver, British Columbia, Canada
University of Western Ontario
London, Ontario, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Saskatchewan Cancer Agency - Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Marien Hospital Duesseldorf
Düsseldorf, , Germany
Universitaetsklinik Frankfurt
Frankfurt, , Germany
Medizinische Hochschule Hanover, Hannover Medical School
Hanover, , Germany
Universitaetsklinik um Schleswig-Holstein, UKSH-Campus Kiel
Kiel, , Germany
Inselspital Bern
Bern, , Switzerland
HFR Fribourg - Hopital Cantonal
Fribourg, , Switzerland
Kantonsspital St. Gallen
Sankt Gallen, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OV-AML-1231
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.